Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.66 - $62.58
Previous CloseN/A
Volume212.48K
Average Volume (3M)677.15K
Market Cap
$1.68B
Enterprise Value$1.04B
Total Cash (Recent Filing)$83.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)2.4
Beta1.86
Next Earnings
May 01, 2025EPS Estimate
-1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.39
Shares Outstanding57,296,165
10 Day Avg. Volume620,985
30 Day Avg. Volume677,146
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)49.14
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit32.21
Enterprise Value/Ebitda-2.47
Forecast
1Y Price Target
$56.17Price Target Upside105.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Agios Pharma News
PremiumCompany Announcements
Agios Pharmaceuticals Reports Strong 2024 Financial Results
PremiumCompany Announcements
Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPhase 2 data from the RISE UP study in sickle cell disease have shown highly encouraging results, with superior hemoglobin increase and reduction in vaso-occlusive crises compared to competitors.
Product Pipeline ExpansionMitapivat is expected to have three approved indications by the end of 2026, expanding its potential market significantly.
Regulatory ProgressMitapivat's sNDA is under review with the FDA with a PDUFA date set, and launch preparation is ongoing.
Bears Say
Labeling ConcernsThe updated label for Pyrukynd includes a warning for liver injury, which has been an overhang for AGIO shares, contributing to a significant decline in stock value.
Risk PerceptionInvestor concerns exist regarding the efficacy bar, the risk of hepatocellular injury, and the overall risk/benefit of the drug.
Safety ConcernsConcerns over hepatocellular injury have negatively impacted AGIO stock, which is down approximately 45% due to these issues observed in thalassemia patients.
---
Ownership Overview
1.50% Insiders
26.28% Mutual Funds
0.08% Other Institutional Investors
54.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $26.66 and its highest was $62.58 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.68B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is May 01, 2025 which is in 28 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Feb 13, 2025. The company reported -$1.44 earnings per share for the quarter, beating the consensus estimate of -$1.691 by $0.251.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.78.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 57,296,165 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.44 in its last earnings report, beating expectations of -$1.691. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
---
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$56.17 (105.00% Upside)
$56.17 (105.00% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 78.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.05%
12-Months-Change
Fundamentals
Return on Equity
57.29%
Trailing 12-Months
Asset Growth
77.48%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
---
AGIO Company Deck
---
AGIO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the development pipeline, with major milestones expected in thalassemia and sickle cell disease. Strong revenue growth from PYRUKYND and a robust financial position are positive indicators. However, higher operating expenses and limited revenue growth for PK deficiency were noted as challenges.Read More>---
AGIO Stock 12 Month Forecast
Average Price Target
$56.17
▲(105.00% Upside)
Technical Analysis
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Best Analysts Covering AGIO
1 Year
1 Year Success Rate
13/25 ratings generated profit
1 Year Average Return
+11.45%
reiterated a buy rating last month
Copying Gregory Renza's trades and holding each position for 1 Year would result in 52.00% of your transactions generating a profit, with an average return of +11.45% per trade.
---